An aptamer-antibody complex (oligobody) as a novel delivery platform for targeted cancer therapies

Journal of Controlled Release

Volumn 229, Issue , 2016, Pages 1-9

  Heo, Kyun ^a   Min, Sung Won ^a   Sung, Ho Jin ^a   Kim, Han Gyul ^a   Kim, Hyun Jung ^a   Kim, Yun Hee ^a   Choi, Beom Kyu ^a   Han, Sewoon ^b   Chung, Seok ^b   Lee, Eun Sook ^a   Chung, Junho ^c   Kim, In Hoo ^a  

^a National Cancer Center   (South Korea)

^b Korea University   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

Antibody; Aptamer; Cotinine; Oligobody; Targeted cancer therapy

Indexed keywords

BINDING ENERGY; DISEASES; OLIGONUCLEOTIDES; ONCOLOGY; PHARMACOKINETICS; TUMORS;

ANTIBODY COMPLEXES; APTAMERS; COTININE; OLIGOBODY; PROOF OF PRINCIPLES; SYSTEMIC ADMINISTRATION; TARGETED CANCER THERAPY; THERAPEUTIC POTENTIALS;

ANTIBODIES;

BEVACIZUMAB; COTININE; DRUG CARRIER; OLIGOBODY; PEGAPTANIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; APTAMER; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

A549 CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER SIZE; CAPILLARY ENDOTHELIAL CELL; COMPLEX FORMATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG PENETRATION; FEMALE; HALF LIFE TIME; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; MALE; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; A-549 CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CHEMISTRY; DRUG DELIVERY SYSTEM; HEP-G2 CELL LINE; IMMUNOLOGY; LUNG NEOPLASMS; METABOLISM; NUDE MOUSE; UMBILICAL VEIN ENDOTHELIAL CELL;

A549 CELLS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APTAMERS, NUCLEOTIDE; COTININE; DRUG DELIVERY SYSTEMS; FEMALE; HEP G2 CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LUNG NEOPLASMS; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR TARGETED THERAPY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84962596774     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2016.03.006     Document Type: Article

References (28)

1. A.M. Scott, J.D. Wolchok, and L.J. Old Antibody therapy of cancer Nat. Rev. Cancer 12 2012 278 287
2. P. Chames, M. Van Regenmortel, E. Weiss, and D. Baty Therapeutic antibodies: successes, limitations and hopes for the future Br. J. Pharmacol. 157 2009 220 233
3. R.A. Beckman, L.M. Weiner, and H.M. Davis Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors Cancer 109 2007 170 179
4. C. Tuerk, and L. Gold Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase Science 249 1990 505 510
5. J. Banerjee, and M. Nilsen-Hamilton Aptamers: multifunctional molecules for biomedical research J. Mol. Med. 91 2013 1333 1342
6. W. Tan, H. Wang, Y. Chen, X. Zhang, H. Zhu, C. Yang, R. Yang, and C. Liu Molecular aptamers for drug delivery Trends Biotechnol. 29 2011 634 640
7. A.D. Keefe, S. Pai, and A. Ellington Aptamers as therapeutics Nat. Rev. Drug Discov. 9 2010 537 550
8. J. Zhou, and J.J. Rossi Cell-type-specific, aptamer-functionalized agents for targeted disease therapy Mol. Ther. Nucleic Acids 3 2014 e169
9. C.L. Esposito, S. Catuogno, V. de Franciscis, and L. Cerchia New insight into clinical development of nucleic acid aptamers Discov. Med. 11 2011 487 496
10. S.A. Vinores Pegaptanib in the treatment of wet, age-related macular degeneration Int. J. Nanomedicine 1 2006 263 268
11. D.J. Pieramici, and M.D. Rabena Anti-VEGF therapy: comparison of current and future agents Eye (Lond.) 22 2008 1330 1336
12. J.M. Healy, S.D. Lewis, M. Kurz, R.M. Boomer, K.M. Thompson, C. Wilson, and T.G. McCauley Pharmacokinetics and biodistribution of novel aptamer compositions Pharm. Res. 21 2004 2234 2246
13. J.G. Bruno A review of therapeutic aptamer conjugates with emphasis on new approaches Pharmaceuticals (Basel) 6 2013 340 357
14. E.R. Bowman, and H. McKennis Jr. Studies on the metabolism of (-)-continine in the human J. Pharmacol. Exp. Ther. 135 1962 306 311
15. O. Riah, J.C. Dousset, P. Courriere, J.L. Stigliani, G. Baziard-Mouysset, and Y. Belahsen Evidence that nicotine acetylcholine receptors are not the main targets of cotinine toxicity Toxicol. Lett. 109 1999 21 29
16. I. Kim, and M.A. Huestis A validated method for the determination of nicotine, cotinine, trans-3′-hydroxycotinine, and norcotinine in human plasma using solid-phase extraction and liquid chromatography-atmospheric pressure chemical ionization-mass spectrometry J. Mass Spectrom. 41 2006 815 821
17. S. Park, D. Hwang, and J. Chung Cotinine-conjugated aptamer/anti-cotinine antibody complexes as a novel affinity unit for use in biological assays Exp. Mol. Med. 44 2012 554 561
18. S. Han, J.J. Yan, Y. Shin, J.J. Jeon, J. Won, H.E. Jeong, R.D. Kamm, Y.J. Kim, and S. Chung A versatile assay for monitoring in vivo-like transendothelial migration of neutrophils Lab Chip 12 2012 3861 3865
19. J.S. de Jong, P.J. van Diest, and J.P. Baak Heterogeneity and reproducibility of microvessel counts in breast cancer Lab. Investig. 73 1995 922 926
20. J. Ruckman, L.S. Green, J. Beeson, S. Waugh, W.L. Gillette, D.D. Henninger, L. Claesson-Welsh, and N. Janjić 2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain J. Biol. Chem. 273 1998 20556 20567
21. R.R. White, B.A. Sullenger, and C.P. Rusconi Developing aptamers into therapeutics J. Clin. Invest. 106 2000 929 934
22. X. Pei, J. Zhang, and J. Liu Clinical applications of nucleic acid aptamers in cancer Mol. Clin. Oncol. 2 2014 341 348
23. H. Sun, X. Zhu, P.Y. Lu, R.R. Rosato, W. Tan, and Y. Zu Oligonucleotide aptamers: new tools for targeted cancer therapy Mol. Ther. Nucleic Acids 3 2014 e182
24. J.W. Lee, H.J. Kim, and K. Heo Therapeutic aptamers: developmental potential as anticancer drugs BMB Rep. 48 2015 234 237
25. R.K. Jain Transport of molecules, particles, and cells in solid tumors Annu. Rev. Biomed. Eng. 1 1999 241 263
26. M.E. Ackerman, D. Pawlowski, and K.D. Wittrup Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids Mol. Cancer Ther. 7 2008 2233 2240
27. K.D. Wittrup, G.M. Thurber, M.M. Schmidt, and J.J. Rhoden Practical theoretic guidance for the design of tumor-targeting agents Methods Enzymol. 503 2012 255 268
28. R.E. Kontermann Dual targeting strategies with bispecific antibodies MAbs 4 2012 182 197